What is VolitionRx?
VolitionRx operates at the intersection of biotechnology and clinical diagnostics, specializing in the development of cost-effective, accessible blood tests for the detection and monitoring of life-altering diseases. The company's core focus lies in the science of epigenetics, specifically targeting conditions such as various cancers and diseases associated with NETosis, including sepsis. By providing clinicians with actionable data through simple blood-based assays, VolitionRx aims to improve patient outcomes and reduce the burden on healthcare systems globally. Its business model relies on the commercialization of these diagnostic tools through strategic partnerships and direct market entry, supported by a robust intellectual property portfolio.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $11.3M across 4 funding rounds:
Private Equity
$1.5M
Debt
$5.5M
Stock/Share Issuance
$2M
Other Financing Round
$2.3M
Private Equity (2022): $1.5M with participation from Namur Invest Capital Risk
Debt (2023): $5.5M, investors not publicly disclosed
Stock/Share Issuance (2026): $2M supported by The Lind Partners
Other Financing Round (2026): $2.3M featuring Namur Invest and Wallonie Entreprendre
Key Investors in VolitionRx
The Lind Partners
The Lind Partners is an institutional fund manager and leading provider of growth capital to small- and mid-cap companies publicly traded in the US, Canada, Australia and the UK.
Namur Invest
Namur Invest is a public-private partnership that funds projects demonstrating development potential and creates added value through equity funds and unsecured loans.
Wallonie Entreprendre
Wallonie Entreprendre is a Belgian-based entity focused on supporting regional business growth and strengthening the financial structure of local enterprises.
What's next for VolitionRx?
With the recent infusion of $2.3M, VolitionRx is well-positioned to transition into a more aggressive phase of clinical validation and market expansion. The strategic focus will likely shift toward scaling the manufacturing of its diagnostic kits and expanding its regulatory footprint in key international markets. Furthermore, the company is expected to prioritize the integration of its NETosis-related diagnostic solutions into standard clinical workflows, thereby solidifying its market position as a pioneer in epigenetic monitoring. As the firm matures, the emphasis will remain on achieving sustainable growth through innovation, ensuring that its diagnostic pipeline addresses the critical unmet needs in oncology and inflammatory disease management.
See full VolitionRx company page
